Ajanta Pharma is currently trading at Rs 1306.00, up by 2.95 points or 0.23% from its previous closing of Rs 1303.05 on the BSE.
The scrip opened at Rs 1305.00 and has touched a high and low of Rs 1319.45 and Rs 1282.10 respectively. So far 32723 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 968.86 on 05-Feb-2015.
Last one week high and low of the scrip stood at Rs. 1319.45 and Rs. 1212.00 respectively. The current market cap of the company is Rs. 11484.16 crore.
The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 10.76% and 15.46% respectively.
Ajanta Pharma has reported 21.99% rise in its net profit at Rs 103.34 crore for the quarter ended December 31, 2015 as compared to Rs 84.71 crore for the same quarter in the previous year. The company’s total income has increased by 15.02% to Rs 424.23 crore for the quarter under review from Rs 368.84 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 19.60% rise in its net profit after taxes, minority interest and share of profit / (loss) of associates of Rs 111.30 crore for the quarter ended December 31, 2015 as compared to Rs 93.06 crore for the same quarter in the previous year. Total income of the company has increased by 15.03% at Rs 474.38 crore for quarter under review as compared to Rs 412.39 crore for the quarter ended December 31, 2014.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: